(This "Intro Box" is NOT maintained byEPGL Medical Sciences and is intended solely as a quick information source on ihub. For more detailed, up-to-date information on EPGL Medical Sciences, please go the company website by clicking the link above..)
EP Global Communications, Inc. (ticker EPGL) will change its name to EPGL Medical Sciences, Inc. in early 2013. EPGL Medical Sciences, Inc. is a new biomedical device manufacturing and marketing company. The Company is focused on developing and marketing medical devices for both diagnosis and treatment of chronic pain. EPGL Med's first medical device, the MPDD, will be released in 2013 to awaiting physicians worldwide. The FDA cleared MPDD medical device can help physicians detect the exact point of pain origination in muscles as never before. The Company is currently working to invent and develop additional cutting edge medical device technology products to introduce subsequently to the MPDD, including biomedical devices which utilize Bio-Micro-Electro Mechanical Systems technology (Bio-MEMS). Bio-MEMS is one of the fastest growing and promising new frontiers in medical technology today with possibilities in both medical diagnostic and treatment applications.
EPGL Medical Science's Competitive Edge
As of July 27, 2012, EP Global Communications, Inc. (EPGL) has successfully been restructured by Pricewaterhouse Coopers (PwC), which is the world's largest financial accounting firm. PwC, along with all other major debt holders, have converted 100% of the Company's debt to equity, estimated to be $10 million USD, becoming major equity partners in the Company. Via the restructuring and as previously announced in public statements, EPGL will now move ahead with plans to enter the growing medical device industry. EPGLD, through acquisition, now holds rights to at least one FDA 510k cleared medical device. The Company recently announced it has appointed Corey W. Hunter M.D. as Company Medical Director and Chairman of the Scientific Advisory Board.
EPGL Medical Sciences, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body. The combined national and international market for the MPDD device is estimated at $4.5 billion dollars annually in device sales and recurrent education and training revenues.
EPGL Medical Science's Latest Developments
EPGL Medical Science's will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL has several new devices in development which are being developed with the latest smart platforms in mind. "Physicians using our devices will be able to utilize technology such as Google Glass while performing procedures, using our devices and viewing feedback data in real-time. In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation.
In addition to the new technologies EPGL is progressing, the Company is implementing an innovative new approach to medical device marketing with a business model which guarantees residual income from each new device sold. The Company's VIP approach to its physician customers with on-going technical support and educational training, will build strong loyalty to our medical devices. EPGL will reveal its new BioMEMS medical device platform, code named "TopSpin", during a series of conference calls hosted by David T. Markus Ph.D. this week. The calls will take place seven consecutive nights this week, starting Wednesday April 24 and concluding Tuesday April 30, 2013. As one of the top BioMEMS engineers in the world, Dr. Markus along with others, will unveil the importance and value of EPGL's new BioMEMS device platform in today's medical marketplace. The new technology stands to spawn potentially dozens of new medical devices, giving doctors innovative new tools for diagnosis and treatment.
About EPGL Medical Science's Share Structure
EPGL has a share structure of 5 billion authorised shares with approximately 4.5 billion shares restricted and a float of approximately 499 million. Following a very sucessfull Reverse Split EPGL has decreased the float by 90% and increased share holder value by over 400%
. Tthe company has strongly stated many times that they will not sell shares into the retail market. They are here to build a real company and impliment real growth.
EPGL On Twitter
About the MPDD
EPGL Management Team
Contact EPGL Medical Sciences or firstname.lastname@example.org, Phone: 877-287-6175
EPGL Medical Science's Press Release Highlights
| 1. || 10:1 Reverse split to be voted upon by shareholders |
| 2. || All major debt holders have agreed to convert 100% of the company's debt to equity |
| 3. || Authorized shares will remain at the present level with no increase in shares |
| 4. || Exlusive rights to a medical device with FDA 510k clearance for marketing |
| 5. || New equity partners involved via merger |
| 6. || The acquisition will be in exchange for equity in the company resulting in no new debt to company |
| 7. || Current EPGL management will resign |
| 8. || New management with broad experience in the medical device industry will be assigned in coming weeks |
| 9. || Top Physicians and Scientists will be part of the new management |
| 10. || Proxy materials are being prepared and details will be mailed to shareholders about meeting in coming days |
| 11. || Reached a restructuring agreement with the liquidator of AJW funds to convert 100% of the Company's debt into equity |
| 12. || Restructure the Company into a medical device manufacturer |
| 13. || The Company will be given exclusive rights to a promising new medical device which has successfully achieved FDA 510k clearance in the pain diagnosis and management arena |
| 14. || The Company plans to market the device to physicians, allied health care professionals and rehabilitation specialists worldwide |
| 15. || The potential market for this unique medical device is estimated to exceed $4.5 billion dollars annually |
| 16. || Current Company management will resign amicably |
| 17. || New management with broad experience in the medical device industry will be assigned, including top researchers, physicians and scientists |
| 18. || The Company name will change to EP Global Health Sciences, Inc. |
| 19. || Will retain the EPGL ticker symbol |
| 20. || The Company believes this restructuring agreement is an extremely positive development and will offer shareholders and investors the opportunity for a significant potential return on investment |
| 21. || Shareholders will be asked to approve a proposed reverse split of the Company's common stock so as to provide sufficient common shares for increased trading value and to raise funding necessary to implement the marketing plans and programs necessary for successful implementation of the new medical device business |